Review





Similar Products

cwith primary antibody  (EpiCypher)
96
EpiCypher cwith primary antibody
Cwith Primary Antibody, supplied by EpiCypher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cwith primary antibody/product/EpiCypher
Average 96 stars, based on 1 article reviews
cwith primary antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cwith primary antibodies against ets 1  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc cwith primary antibodies against ets 1
Cwith Primary Antibodies Against Ets 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cwith primary antibodies against ets 1/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
cwith primary antibodies against ets 1 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
4◦cwith primary antibodies against cd31  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc 4◦cwith primary antibodies against cd31
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
4◦Cwith Primary Antibodies Against Cd31, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4◦cwith primary antibodies against cd31/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
4◦cwith primary antibodies against cd31 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cwith primary antibodies  (Proteintech)
94
Proteintech cwith primary antibodies
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
Cwith Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cwith primary antibodies/product/Proteintech
Average 94 stars, based on 1 article reviews
cwith primary antibodies - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
4◦cwith primary anti zo-1  (Proteintech)
97
Proteintech 4◦cwith primary anti zo-1
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
4◦Cwith Primary Anti Zo 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4◦cwith primary anti zo-1/product/Proteintech
Average 97 stars, based on 1 article reviews
4◦cwith primary anti zo-1 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
◦cwith primary antibodies targeting β actin  (Proteintech)
96
Proteintech ◦cwith primary antibodies targeting β actin
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
◦Cwith Primary Antibodies Targeting β Actin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/◦cwith primary antibodies targeting β actin/product/Proteintech
Average 96 stars, based on 1 article reviews
◦cwith primary antibodies targeting β actin - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cwith primary antibodies against th  (Novus Biologicals)
96
Novus Biologicals cwith primary antibodies against th
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
Cwith Primary Antibodies Against Th, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cwith primary antibodies against th/product/Novus Biologicals
Average 96 stars, based on 1 article reviews
cwith primary antibodies against th - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cwith primary antibody against plxnb3  (Danaher Inc)
86
Danaher Inc cwith primary antibody against plxnb3
FIGURE 1 Cerebral vessels lesion and elevated <t>CD31</t> levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.
Cwith Primary Antibody Against Plxnb3, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cwith primary antibody against plxnb3/product/Danaher Inc
Average 86 stars, based on 1 article reviews
cwith primary antibody against plxnb3 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


FIGURE 1 Cerebral vessels lesion and elevated CD31 levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Article Title: Pathological angiogenesis was associated with cerebrovascular lesion and neurodegeneration in Alzheimer's disease.

doi: 10.1002/alz.14521

Figure Lengend Snippet: FIGURE 1 Cerebral vessels lesion and elevated CD31 levels related to tau pathology in human AD brains. Representative western blots of the level of CD31 (endothelial marker), αSMA (smooth muscle marker), and PDGFRβ (pericyte marker) in separated cerebral vessels of human non-ADD (n = 9) and AD brains (n = 20). Relative expression of αSMA and PDGFRβ normalized to CD31. (A) While both αSMA/CD31 and PDGFRβ/CD31 in cerebral vessels were reduced in human AD brains compared to non-AD brains, CD31 levels showed no difference between the two groups. (B) Schematic of extraction of soluble (TBS fraction), membrane (TBSX fraction) and insoluble proteins (GuHCl fraction) from frozen human brains by a three–step ultracentrifugation. (C) Quantification of occludin, Claudin-5, and CD31 in TBSX fraction by ELISA. Both occludin/CD31 and Claudin-5/CD31 were reduced in human AD brains (n = 7) compared to non-ADD brains (n = 24). (D) Quantification of Aβ42, Aβ40 and pTau181 in GuHCl fraction by MSD. The high pathological group is defined as having levels of Aβ42, Aβ40, or pTau181 greater than the median of the AD group. (E) Univariate or multivariate analyses was used to test associations between Aβ42, Aβ40, pTau181 in GuHCl fraction and CD31 in TBSX fraction with age, sex, and APOE genotype as covariates. Group differences were assessed using ANCOVA adjusted age, sex, and APOE genotype, following by Bonferroni multiple comparison tests. *p < 0.05, **p < 0.01. AD, Alzheimer’s disease; ANCOVA, analysis of covariance; APOE, apolipoprotein E.

Article Snippet: The sections were then blocked with blocking buffer (5% normal goat serum, 0.3% Triton ×-100 in phosphate buffered saline [PBS]) for 1 h at room temperature and incubated overnight at 4◦Cwith primary antibodies against CD31 (CST, 3528S, 1:200) and CD13 (Proteintech, 66211-1-Ig, 1:200).

Techniques: Western Blot, Marker, Expressing, Extraction, Membrane, Enzyme-linked Immunosorbent Assay, Comparison